|
1
|
Levstek T, Breznik N, Vujkovac B, Nowak A, Trebušak Podkrajšek K. Dynamics of Leukocyte Telomere Length in Patients with Fabry Disease. Biomedicines 2024; 12:1724. [PMID: 39200189 PMCID: PMC11351930 DOI: 10.3390/biomedicines12081724] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2024] [Revised: 07/26/2024] [Accepted: 08/01/2024] [Indexed: 09/02/2024] Open
Abstract
Fabry disease (FD) leads to significant morbidity and mortality, which may indicate accelerated ageing. However, it is still unclear whether there is a relationship between telomere length (TL), a marker of biological ageing, and disease outcome. We aimed to examine the relationship between leukocyte TL (LTL) dynamics and the presence of advanced disease stages and/or late complications of FD, including hypertrophic cardiomyopathy, nephropathy and stroke, both cross-sectionally and longitudinally. DNA was extracted from peripheral blood leukocytes and quantitative PCR was utilized to determine relative LTL in 99 Fabry patients. In the longitudinal analysis, we included 50 patients in whom at least three measurements were performed over a period of 5-10 years. The results showed a significant inverse correlation between LTL and age (ρ = -0.20, p = 0.05). No significant differences in LTL were found between females and males (p = 0.79) or between patients receiving disease-specific therapy and those without (p = 0.34). In a cross-sectional analysis, no association was found between the presence (p = 0.15) or number (p = 0.28) of advanced stages of the disease and/or late complications and LTL. Similarly, in a longitudinal analysis, no difference in LTL dynamics was found regarding the presence (p = 0.16) of advanced stage organ involvement and/or late complications or their number. These findings indicate that LTL dynamics in adulthood may not be a reliable indicator of disease outcomes in Fabry patients. Therefore, LTL may more accurately reflect the disease burden in early life, when TL is primarily determined.
Collapse
Affiliation(s)
- Tina Levstek
- Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia
- Clinical Institute for Special Laboratory Diagnostics, University Children’s Hospital, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia
| | - Nika Breznik
- Clinical Institute for Special Laboratory Diagnostics, University Children’s Hospital, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia
| | - Bojan Vujkovac
- Centre for Fabry Disease, General Hospital Slovenj Gradec, 2380 Slovenj Gradec, Slovenia
| | - Albina Nowak
- Department of Endocrinology and Clinical Nutrition, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland
- Department of Internal Medicine, Psychiatry University Clinic Zurich, 8091 Zurich, Switzerland
| | - Katarina Trebušak Podkrajšek
- Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia
- Clinical Institute for Special Laboratory Diagnostics, University Children’s Hospital, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia
| |
Collapse
|
|
2
|
Lo Curto A, Taverna S, Costa MA, Passantino R, Augello G, Adamo G, Aiello A, Colomba P, Zizzo C, Zora M, Accardi G, Candore G, Francofonte D, Di Chiara T, Alessandro R, Caruso C, Duro G, Cammarata G. Can Be miR-126-3p a Biomarker of Premature Aging? An Ex Vivo and In Vitro Study in Fabry Disease. Cells 2021; 10:356. [PMID: 33572275 PMCID: PMC7915347 DOI: 10.3390/cells10020356] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2020] [Revised: 02/04/2021] [Accepted: 02/05/2021] [Indexed: 12/11/2022] Open
Abstract
Fabry disease (FD) is a lysosomal storage disorder (LSD) characterized by lysosomal accumulation of glycosphingolipids in a wide variety of cytotypes, including endothelial cells (ECs). FD patients experience a significantly reduced life expectancy compared to the general population; therefore, the association with a premature aging process would be plausible. To assess this hypothesis, miR-126-3p, a senescence-associated microRNA (SA-miRNAs), was considered as an aging biomarker. The levels of miR-126-3p contained in small extracellular vesicles (sEVs), with about 130 nm of diameter, were measured in FD patients and healthy subjects divided into age classes, in vitro, in human umbilical vein endothelial cells (HUVECs) "young" and undergoing replicative senescence, through a quantitative polymerase chain reaction (qPCR) approach. We confirmed that, in vivo, circulating miR-126 levels physiologically increase with age. In vitro, miR-126 augments in HUVECs underwent replicative senescence. We observed that FD patients are characterized by higher miR-126-3p levels in sEVs, compared to age-matched healthy subjects. We also explored, in vitro, the effect on ECs of glycosphingolipids that are typically accumulated in FD patients. We observed that FD storage substances induced in HUVECs premature senescence and increased of miR-126-3p levels. This study reinforces the hypothesis that FD may aggravate the normal aging process.
Collapse
Affiliation(s)
- Alessia Lo Curto
- Institute for Research and Biomedical Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy; (A.L.C.); (S.T.); (G.A.); (G.A.); (P.C.); (C.Z.); (M.Z.); (D.F.); (R.A.); (G.D.)
| | - Simona Taverna
- Institute for Research and Biomedical Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy; (A.L.C.); (S.T.); (G.A.); (G.A.); (P.C.); (C.Z.); (M.Z.); (D.F.); (R.A.); (G.D.)
| | - Maria Assunta Costa
- Institute of Byophysics, National Research Council (CNR), 90146 Palermo, Italy; (M.A.C.); (R.P.)
| | - Rosa Passantino
- Institute of Byophysics, National Research Council (CNR), 90146 Palermo, Italy; (M.A.C.); (R.P.)
| | - Giuseppa Augello
- Institute for Research and Biomedical Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy; (A.L.C.); (S.T.); (G.A.); (G.A.); (P.C.); (C.Z.); (M.Z.); (D.F.); (R.A.); (G.D.)
| | - Giorgia Adamo
- Institute for Research and Biomedical Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy; (A.L.C.); (S.T.); (G.A.); (G.A.); (P.C.); (C.Z.); (M.Z.); (D.F.); (R.A.); (G.D.)
| | - Anna Aiello
- Laboratory of Immunopathology and Immunosenescence, Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, 90134 Palermo, Italy; (A.A.); (G.A.); (G.C.); (C.C.)
| | - Paolo Colomba
- Institute for Research and Biomedical Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy; (A.L.C.); (S.T.); (G.A.); (G.A.); (P.C.); (C.Z.); (M.Z.); (D.F.); (R.A.); (G.D.)
| | - Carmela Zizzo
- Institute for Research and Biomedical Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy; (A.L.C.); (S.T.); (G.A.); (G.A.); (P.C.); (C.Z.); (M.Z.); (D.F.); (R.A.); (G.D.)
| | - Marco Zora
- Institute for Research and Biomedical Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy; (A.L.C.); (S.T.); (G.A.); (G.A.); (P.C.); (C.Z.); (M.Z.); (D.F.); (R.A.); (G.D.)
| | - Giulia Accardi
- Laboratory of Immunopathology and Immunosenescence, Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, 90134 Palermo, Italy; (A.A.); (G.A.); (G.C.); (C.C.)
| | - Giuseppina Candore
- Laboratory of Immunopathology and Immunosenescence, Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, 90134 Palermo, Italy; (A.A.); (G.A.); (G.C.); (C.C.)
| | - Daniele Francofonte
- Institute for Research and Biomedical Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy; (A.L.C.); (S.T.); (G.A.); (G.A.); (P.C.); (C.Z.); (M.Z.); (D.F.); (R.A.); (G.D.)
| | - Tiziana Di Chiara
- Department PROMISE, School of Medicine, University of Palermo, 90127 Palermo, Italy;
| | - Riccardo Alessandro
- Institute for Research and Biomedical Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy; (A.L.C.); (S.T.); (G.A.); (G.A.); (P.C.); (C.Z.); (M.Z.); (D.F.); (R.A.); (G.D.)
- Department of Biomedicine, Neuroscience and Advanced Diagnostics-Section of Biology and Genetics, University of Palermo, 90127 Palermo, Italy
| | - Calogero Caruso
- Laboratory of Immunopathology and Immunosenescence, Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, 90134 Palermo, Italy; (A.A.); (G.A.); (G.C.); (C.C.)
| | - Giovanni Duro
- Institute for Research and Biomedical Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy; (A.L.C.); (S.T.); (G.A.); (G.A.); (P.C.); (C.Z.); (M.Z.); (D.F.); (R.A.); (G.D.)
| | - Giuseppe Cammarata
- Institute for Research and Biomedical Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy; (A.L.C.); (S.T.); (G.A.); (G.A.); (P.C.); (C.Z.); (M.Z.); (D.F.); (R.A.); (G.D.)
| |
Collapse
|
|
3
|
Foster A, Khan Z, Siddiqui A, Singh S, Atere M, Nfonoyim JM. It's complicated: A case report on a COVID-19-positive HIV patient presenting with rhabdomyolysis and acute kidney injury. SAGE Open Med Case Rep 2020; 8:2050313X20965423. [PMID: 33117541 PMCID: PMC7570771 DOI: 10.1177/2050313x20965423] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2020] [Accepted: 09/21/2020] [Indexed: 02/06/2023] Open
Abstract
The SARS-Cov-2/COVID-19 pandemic in early 2020 has had a devastating impact on health systems around the world. While viral pneumonia remains the most common complication, reports are surfacing of cases with neurological, cardiac, and renal involvement. Even less is known about the implications in special high-risk populations. In this report, we discuss a unique case of an HIV-positive patient in New York City who presented with a 2-week history of worsening fatigue, cough, dyspnea, and myalgias and was found to have COVID-19 pneumonia and acute kidney injury. He was managed for severe uremic metabolic acidosis and electrolyte abnormalities with emergent hemodialysis and supportive therapy with subsequent improvement. Direct involvement of SARS-CoV-2 and pneumonia-induced rhabdomyolysis were identified as the precipitating factors of his acute kidney injury. The pathophysiologic mechanisms of acute kidney injury, SARS-CoV-2 renal tropism, and the impact of highly active antiretroviral therapy on COVID-19 pneumonia are discussed. We highlight the importance of clinician awareness of this potentially fatal complication of COVID-19 pneumonia, particularly in the HIV-positive population as early recognition and management can have favorable outcomes.
Collapse
Affiliation(s)
- Allison Foster
- College of Medicine, American University of Antigua, New York, NY, USA
- Richmond University Medical Center, Staten Island, NY, USA
| | - Zohaib Khan
- College of Medicine, American University of Antigua, New York, NY, USA
| | - Aisha Siddiqui
- College of Medicine, American University of Antigua, New York, NY, USA
| | - Sukhdev Singh
- College of Medicine, American University of Antigua, New York, NY, USA
| | - Muhammed Atere
- Department of Internal Medicine, Richmond University Medical Center, Staten Island, NY, USA
| | - Jay M Nfonoyim
- Chief of Critical Care and Clinical Medicine, Richmond University Medical Center, Staten Island, NY, USA
| |
Collapse
|
|
4
|
Ebert T, Pawelzik SC, Witasp A, Arefin S, Hobson S, Kublickiene K, Shiels PG, Bäck M, Stenvinkel P. Inflammation and Premature Ageing in Chronic Kidney Disease. Toxins (Basel) 2020; 12:E227. [PMID: 32260373 PMCID: PMC7232447 DOI: 10.3390/toxins12040227] [Citation(s) in RCA: 117] [Impact Index Per Article: 29.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2020] [Revised: 03/20/2020] [Accepted: 03/29/2020] [Indexed: 02/06/2023] Open
Abstract
Persistent low-grade inflammation and premature ageing are hallmarks of the uremic phenotype and contribute to impaired health status, reduced quality of life, and premature mortality in chronic kidney disease (CKD). Because there is a huge global burden of disease due to CKD, treatment strategies targeting inflammation and premature ageing in CKD are of particular interest. Several distinct features of the uremic phenotype may represent potential treatment options to attenuate the risk of progression and poor outcome in CKD. The nuclear factor erythroid 2-related factor 2 (NRF2)-kelch-like erythroid cell-derived protein with CNC homology [ECH]-associated protein 1 (KEAP1) signaling pathway, the endocrine phosphate-fibroblast growth factor-23-klotho axis, increased cellular senescence, and impaired mitochondrial biogenesis are currently the most promising candidates, and different pharmaceutical compounds are already under evaluation. If studies in humans show beneficial effects, carefully phenotyped patients with CKD can benefit from them.
Collapse
Affiliation(s)
- Thomas Ebert
- Karolinska Institutet, Department of Clinical Science, Intervention and Technology, Division of Renal Medicine, SE-141 86 Stockholm, Sweden; (A.W.); (S.A.); (S.H.); (K.K.)
| | - Sven-Christian Pawelzik
- Karolinska Institutet, Department of Medicine Solna, Cardiovascular Medicine Unit, SE-171 76 Stockholm, Sweden; (S.-C.P.); (M.B.)
- Karolinska University Hospital, Theme Heart and Vessels, Division of Valvular and Coronary Disease, SE-171 76 Stockholm, Sweden
| | - Anna Witasp
- Karolinska Institutet, Department of Clinical Science, Intervention and Technology, Division of Renal Medicine, SE-141 86 Stockholm, Sweden; (A.W.); (S.A.); (S.H.); (K.K.)
| | - Samsul Arefin
- Karolinska Institutet, Department of Clinical Science, Intervention and Technology, Division of Renal Medicine, SE-141 86 Stockholm, Sweden; (A.W.); (S.A.); (S.H.); (K.K.)
| | - Sam Hobson
- Karolinska Institutet, Department of Clinical Science, Intervention and Technology, Division of Renal Medicine, SE-141 86 Stockholm, Sweden; (A.W.); (S.A.); (S.H.); (K.K.)
| | - Karolina Kublickiene
- Karolinska Institutet, Department of Clinical Science, Intervention and Technology, Division of Renal Medicine, SE-141 86 Stockholm, Sweden; (A.W.); (S.A.); (S.H.); (K.K.)
| | - Paul G. Shiels
- University of Glasgow, Wolfson Wohl Cancer Research Centre, College of Medical, Veterinary & Life Sciences, Institute of Cancer Sciences, Glasgow G61 1QH, UK;
| | - Magnus Bäck
- Karolinska Institutet, Department of Medicine Solna, Cardiovascular Medicine Unit, SE-171 76 Stockholm, Sweden; (S.-C.P.); (M.B.)
- Karolinska University Hospital, Theme Heart and Vessels, Division of Valvular and Coronary Disease, SE-171 76 Stockholm, Sweden
| | - Peter Stenvinkel
- Karolinska Institutet, Department of Clinical Science, Intervention and Technology, Division of Renal Medicine, SE-141 86 Stockholm, Sweden; (A.W.); (S.A.); (S.H.); (K.K.)
| |
Collapse
|